Tentolouris N, Doulgerakis D, Moyssakis I, Kyriaki D, Makrilakis K, Kosmadakis G, Stamatiadis D, Katsilambros N, Stathakis C
1st Department of Propedeutic Medicine, Athens University Medical School, 115 21 Athens, Greece.
Horm Metab Res. 2004 Oct;36(10):721-7. doi: 10.1055/s-2004-826022.
To compare plasma adiponectin levels between healthy controls and patients with chronic renal failure and to examine for a relationship between plasma adiponectin levels and ischemic heart disease as well as aortic distensibility which is an early marker of atherosclerosis.
We included 89 patients with CRF (45 on and 44 not on hemodialysis) and 70 controls in a cross-sectional study. Plasma adiponectin levels were measured by radioimmunoassay. Aortic distensibility was assessed by high-resolution ultrasonography.
Plasma adiponectin levels were significantly almost twice as high in patients with renal failure compared to controls (9.7 +/- 1.1 vs. 5.4 +/- 0.6 microg/ml, p < 0.0001). No significant differences were found between renal patients on hemodialysis and not on hemodialysis (p = 0.71). Multivariate linear regression analysis in the renal patient group demonstrated a significant negative relationship between plasma adiponectin levels and ischemic heart disease (p = 0.02). The same analysis in the control subjects group showed a significant, negative relationship between plasma adiponectin levels and body mass index (p = 0.02) and a highly significant positive relationship with the high density lipoprotein cholesterol (p < 0.0001). In the total study population, glomerular filtration rate was the only independent predictor of plasma adiponectin concentrations. Aortic distensibility was lower in renal patients than in controls at a high level of significance (p < 0.0001). However, no significant relationship could be found between plasma adiponectin and aortic distensibility in either the controls or the renal patients.
Plasma adiponectin levels are almost twice as high in patients with chronic renal failure in comparison with healthy controls, but not different between renal patients on and those not on hemodialysis. In addition, low plasma adiponectin levels are strongly associated with ischemic heart disease, but not with aortic distensibility in chronic renal failure.
比较健康对照组与慢性肾衰竭患者的血浆脂联素水平，并探讨血浆脂联素水平与缺血性心脏病以及动脉粥样硬化早期标志物主动脉扩张性之间的关系。
我们纳入了89例慢性肾衰竭患者（45例接受血液透析，44例未接受血液透析）和70例对照进行横断面研究。采用放射免疫分析法测定血浆脂联素水平。通过高分辨率超声评估主动脉扩张性。
与对照组相比，肾衰竭患者的血浆脂联素水平显著升高，几乎是对照组的两倍（9.7±1.1对5.4±0.6微克/毫升，p<0.0001）。接受血液透析和未接受血液透析的肾病患者之间未发现显著差异（p = 0.71）。肾病患者组的多因素线性回归分析显示血浆脂联素水平与缺血性心脏病之间存在显著负相关（p = 0.02）。对照组的相同分析显示血浆脂联素水平与体重指数之间存在显著负相关（p = 0.02），与高密度脂蛋白胆固醇之间存在高度显著正相关（p<0.0001）。在整个研究人群中，肾小球滤过率是血浆脂联素浓度的唯一独立预测因素。肾病患者的主动脉扩张性显著低于对照组（p<0.0001）。然而，在对照组或肾病患者中，血浆脂联素与主动脉扩张性之间均未发现显著关系。
与健康对照组相比，慢性肾衰竭患者的血浆脂联素水平几乎高出两倍，但接受血液透析和未接受血液透析的肾病患者之间无差异。此外，低血浆脂联素水平与缺血性心脏病密切相关，但与慢性肾衰竭患者的主动脉扩张性无关。
